Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GS-5319
- Development stage
- Phase 1
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
GS-5319 is an **investigational small molecule anticancer drug** currently being evaluated in Phase 1 clinical trials for adults with advanced solid tumors that harbor deletions in the methylthioadenosine phosphorylase (MTAP) gene. MTAP normally plays a role in cell growth, and tumors with MTAP deletion represent a molecularly defined patient subgroup. The primary goal of ongoing studies is to determine the safety, tolerability, and recommended dose for GS-5319 monotherapy in this patient population. Its mechanism of action, molecular target, and chemical structure have not been publicly disclosed. GS-5319 is being developed by Gilead Sciences[3][5][6].
Beyond the preview
Go deeper on GS-5319.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GS-5319.